You are here:Home-Chemical Inhibitors & Agonists-Nuclear Receptor/Transcription Factor-Eukaryotic Initiation Factor (eIF)-eFT226
eFT226

Chemical Structure : eFT226

CAS No.: 2098191-53-6

eFT226 (Zotatifin, eFT 226)

Catalog No.: PC-63308Not For Human Use, Lab Use Only.

eFT226 is a novel, potent and selective eIF4A inhibitor with anti-tumor activity in B-cell malignancies, promotes eIF4A binding to specific mRNA sequences and interferes with the assembly of the eIF4F initiation complex.

Packing Price Stock Quantity
1 mg $958 In stock
5 mg $1880 In stock
10 mg Get quote
25 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Zotatifin (eFT226) is a novel, potent and selective eIF4A inhibitor with anti-tumor activity in B-cell malignancies, promotes eIF4A binding to specific mRNA sequences and interferes with the assembly of the eIF4F initiation complex.
Zotatifin (eFT226) selectively inhibits translation of mRNAs containing longer 5'-UTRs, an increased frequency of uORFs (upstream open reading frame), and polypurine and/or G-quadraplex recognition motifs.
Zotatifin (eFT226) demonstrates potent inhibition of reporter constructs containing a polypurine motif in the 5'-UTR with IC50 of 2 nM.
Zotatifin (eFT226) shows potent anti-proliferative activity (EC50<15 nM) and an induction of apoptosis against a panel of B-cell lymphoma cell lines, dose-dependently decreases the oncogenic drivers c-MYC, CCND1/3, BCL2 or MCL-1.
Zotatifin (eFT226) shows in vivo activity across hematological tumor models.

Physicochemical Properties

M.Wt 487.55
Formula C28H29N3O5
Appearance Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

4-[(5aR,6S,7S,8R,8aS)-7-[(Dimethylamino)methyl]-6,7,8,8a-tetrahydro-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5aH-cyclopenta[4,5]furo[3,2-c]pyridin-5a-yl]benzonitrile

References

1. Peggy A. Thompson, et al. Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-tumor Activity in B-cell Malignancies.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: